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Abstract
Study background: Multidrug resistant Escherichia coli (MDR E. coli) has become a major health concern, and
failure of treatment leads to huge health burden. Aim of the present study was to determine the impact of Mr.
Trivedi’s biofield treatment on E. coli.
Methods: Four MDR clinical lab isolates (LSs) of E. coli (LS 8, LS 9, LS 10, and LS 11) were taken and divided
into two groups i.e. control and biofield treated. Control and treated samples were identified with respect to its
antimicrobial sensitivity assay, biochemical study and biotype number using MicroScan Walk-Away® system. The
analysis was done on day 10 after biofield treatment and compared with its respective control group.
Results: Antimicrobial sensitivity assay showed 50% alteration in sensitivity of total tested antimicrobials in
treated group of MDR E. coli isolates. MIC results showed the alteration in MIC of about 40.63% antimicrobials out
of thirty two tested antimicrobials, after biofield treatment in clinical isolates of E. coli. Ticarcillin/k-clavulanate
showed improved sensitivity (R → I) with decreased MIC value in LS 9 as compared to control. A fourfold and
twofold decreased in MIC values were reported in case of piperacillin/tazobactam (in LS 9) and chloramphenicol (in
LS 8), respectively as compared to respective control. Biochemical study showed a 39.39% alteration in biochemical
reactions after treatment among four isolates of E. coli as compared to control. A significant change in biotype
numbers were reported in three clinical isolates (i.e. LS 8, LS 9, and LS 11) of MDR E. coli as compared to control.
On the basis of changed biotype number (7774 5272) after biofield treatment, organism with maximum probability
was identified as Enterobacter aerogenes in LS 8 as compared to control, (E. coli, 7711 5012).
Conclusion: Overall results suggest that Mr Trivedi’s biofield treatment has a significant effect on altering the
antimicrobial sensitivity, biochemical reactions and biotype number of MDR isolates of E. coli.
Keywords: Escherichia coli; Biofield treatment; Multidrug-resistant;
Antimicrobial susceptibility; Biochemical reaction; Biotyping
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Introduction
Escherichia coli (E. coli) is a Gram-negative, rod shape, and
facultative anaerobic bacteria predominantly found in human colonic
flora. Despite the fact about E. coli, its commensal nature and common
existence in microflora of animal intestine including man, all the E.
coli strains are not harmful; sometimes it causes fatal enteric infections
in humans as well as mammals and birds [1]. Pathogenic strains of E.
coli cause common intestine infection i.e. diarrhea, extra intestinal
infections in humans and animals includes urinary tract infections
(UTI), meningitis, and septicemia [2]. Apart from these diseases,
pathogenic E. coli may be responsible for causing cystitis and
pylonephritis, a major cause in approximately 80% of 130-175 million
human UTIs [3]. Furthermore, E. coli causing extra intestinal
infections are the major Gram-negative bacterial pathogens
responsible for neonatal meningitis, and ranks second in an overall
cause of the disease after group B streptococcus infections [4,5].
During last few years, increasing emergence and wide dissemination of
E. coli isolates show resistance to broad-spectrum antimicrobial agents
[6]. MDR isolates are the basic cause of failure in treatment modalities,
resulting high rate of morbidity and mortality [7]. An emergence of
resistance against multiple antimicrobials drugs is a serious threat to
public health, and sometimes no available antimicrobials will be
effective to treat the infections caused by MDR E. coli [6,8]. Due to
dramatically increase in drug resistance against antibiotics, some
alternate approach is required to later the sensitivity pattern of
antimicrobials. Recently, biofield treatment on pathogenic
microorganism is available as an alternative approach to altering the
sensitivity pattern of various antimicrobials [9,10].
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Biofield as an energy medicine has been included in complementary
and alternative medicine (CAM) therapies, and very commonly
practiced in US by professional healthcare representative [11]. CAM
therapies are very helpful to improve the human wellbeing and health
without having any side effects. Bio-electrographic method is non-
invasive technology used to measure the human biofield which can
evaluate the physical and emotional heath [12]. The energy exists in
various forms that can be produced from different sources such as
potential, electrical, kinetic, magnetic, and nuclear energy.
The cumulative effect of bio-magnetic and electric field that
surrounds the human body is defined as biofield, and the extent of
energy associated with biofield is termed as biofield energy. It can be
monitored using techniques such as electromyography (EMG),
electrocardiography (ECG) and electroencephalogram (EEG) [13]. Mr
Mahendra Kumar Trivedi has the ability to harness the energy from
environment or universe and can transmit into any living or non-living
object(s) around the Universe.
The objects always receive the energy and responding into useful
way via biofield energy and the process is known as biofield treatment.
Mr Trivedi’s unique biofield treatment is also known as The Trivedi
Effect® and it was widely studied in the field of material science [14-16],
agricultural science [17-19], and in biotechnology [20]. In
microbiology, biofield treatment on pathogenic microbes and MDR
isolates had been reported to alter the antimicrobial sensitivity,
biochemical reactions and biotype number [10,21,22].
In continuation of outstanding results of biofield treatment and
clinical significance of MDR E. coli, present work was designed to
evaluate the influence of biofield treatment on MDR isolates of E. coli
with respect to its antimicrobials susceptibility, biochemical reactions
pattern, and biotyping.
Material and Methods
Bacterial isolates, study design and biofield treatment
MDR clinical lab isolates (i.e. LS 8, LS 9, LS 10 and LS 11) of E. coli
were obtained from stored stock cultures in Microbiology Lab, Hinduja
Hospital, Mumbai. Each MDR isolate was divided into two groups i.e.
control and treatment. Treatment groups, in sealed pack were handed
over to Mr Trivedi for biofield treatment under laboratory conditions.
Mr Trivedi provided the treatment through his energy transmission
process to the treated groups without touching the samples.
The biofield treated samples were returned in the similar sealed
condition and further analyzed on day 10 using the standard protocols.
The following parameters like antimicrobial susceptibility, minimum
inhibitory concentration (MIC), biochemical reactions, and biotype
number were measured in all four MDR E. coli isolates by MicroScan
Walk-Away® (Dade Behring Inc., USA) of both control and treated
samples. All antimicrobials and biochemicals were procured from
Sigma Aldrich.
Inoculum preparation
The turbidity standard technique using direct inoculation of E. coli
cell was used in the experiment. Using a sterile wooden applicator stick
or bacteriological loop, the surface of 4-5 large or 5-10 small
morphologically similar culture was touched for well-isolated colonies
from an 18-24 hour non-inhibitory agar plate. Further, colonies were
emulsified in 3 mL of inoculum water (autoclaved deionized water) to
an equivalent of a 0.5 McFarland barium sulfate turbidity standard. 100
μL of the standardized suspension was pipetted into 25 mL of
inoculum water using pluronic and inverted 8-10 times.
Evaluation of antimicrobial susceptibility assay
Antimicrobial susceptibility patterns of MDR lab isolates of E. coli
were studied using MicroScan Walk-Away® using Negative Break Point
Combo (NBPC 30) panel as per the clinical and laboratory standards
institute (CLSI) guidelines. The tests carried out on MicroScan were
miniaturized of the broth dilution susceptibility test that have been
dehydrated. Briefly, the standardized suspension of E. coli were
inoculated, rehydrated, and then subjected to incubation for 16 hours
at 35°C. The detailed experimental procedures and conditions were
followed as per the manufacturer's instructions. The antimicrobial
susceptibility pattern (S: Susceptible, I: Intermediate, R: Resistant, and
EBL: Suspected extended-spectrum beta-lactamases) and MIC values
were determined by observing the lowest antimicrobial concentration
showing growth inhibition [23].
Identification by biochemical study and biotype number
Biochemical studies of each MDR isolates of E. coli were
determined by MicroScan Walk-Away® using NBPC 30 panel system in
both control and treated groups. The biotype number of each MDR
isolates of E. coli in control and treated sample were determined
followed by identification of microorganism by MicroScan Walk-
Away® processed panel data report with the help of biochemical
reaction data [23].
Results and Discussion
Antimicrobial susceptibility study
MDR isolates of E. coli showed altered pattern of antimicrobial
sensitivity as compared to its respective control in all the isolates after
biofield treatment. Results of antimicrobial sensitivity pattern and MIC
values of control and treated MDR isolates of E. coli are summarized in
Tables 1 and 2, respectively. Overall, 50% of tested antimicrobials out
of thirty two, showed alteration in antimicrobial sensitivity pattern
against biofield treated MDR isolates of E. coli. The alterations in
sensitivity pattern after biofield treatment were observed as 40.62% in
LS 8, 6.25% in LS9, 25% in LS 10, and 6.25% in LS 11 (Figure 1) with
respect to control. In this study, very high resistant rates of MDR E.
coli isolates against tested antimicrobials such as ampicillin,
cefotaxime, ceftriaxone, ceftazidime, tetracycline, tobramycin, and
aztreonam had been detected (Table 1).
Enterobacteriaceae, such as E. coli and Klebsiella spp., produce
different beta-lactamase enzymes, some have activity against penicillin,
2nd, and 3rd generation cephalosporin. However, in recent years, the
activity of β-lactamases has been enhanced, as they have the capacity
to hydrolyze the extended spectrum cephalosporin, such as cefotaxime,
ceftriaxone, ceftazidime etc. [24]. Extended spectrum beta-lactamases
(ESBLs) are rapidly evolved group of beta-lactamases enzyme, which
confer resistance not only against beta-lactam antibiotics, but also for
non-penicillin antibiotics [25].
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S. No Antimicrobial
LS 8 LS 9 LS 10 LS 11
C T C T C T C T
1 Amikacin S R R R S R S S
2 Amoxicillin/k-clavulanate S I I I S R R R
3 Ampicillin/sulbactam I R R R R R R R
4 Ampicillin R R R R R R R R
5 Aztreonam EBL? R EBL? EBL? EBL? EBL? EBL? EBL?
6 Cefazolin R R R R R R R R
7 Cefepime R R R R R R R R
8 Cefotaxime EBL? R EBL? EBL? EBL? EBL? EBL? EBL?
9 Cefotetan S I S S S R R R
10 Cefoxitin I R R R S R R R
11 Ceftazidime EBL? R EBL? EBL? EBL EBL? EBL? EBL?
12 Ceftriaxone EBL? R EBL? EBL? EBL EBL? EBL? EBL?
13 Cefuroxime R R R R R R R R
14 Cephalothin R R R R R R R R
15 Chloramphenicol I S R R R R R R
16 Ciprofloxacin R R R R R R R R
17 ESBL-a Scrn EBL? - EBL? EBL? EBL? EBL? EBL? EBL?
18 ESBL-b Scrn EBL? - EBL? EBL? EBL? EBL? EBL? EBL?
19 Gatifloxacin R R R R I R R R
20 Gentamicin R R R R R R R R
21 Imipenem S S S S S S S I
22 Levofloxacin R R R R R R R R
23 Meropenem S I S S S S S R
24 Moxifloxacin R R R R R R R R
25 Nitrofurantoin - - - - - - - -
26 Norfloxacin - - - - - - - -
27 Piperacillin/tazobactam S R I S S I R R
28 Piperacillin R R R R R R R R
29 Tetracycline R R R R R R R R
30 Ticarcillin/k-clavulanate S R R I S I R R
31 Tobramycin R R R R R R R R
32 Trimethoprim/sulfamethoxazole R R R R S R R R
Table 1: Effect of biofield treatment on multidrug resistant lab isolates of Escherichia coli to antimicrobial susceptibility. C: Control; T: Treatment;
R: Resistant; I: Intermediate; S: Susceptible; LS: Lab Isolate; ESBL-a,b Srcn: Extended-Spectrum-β-Lactamase Screen; -: Not tested; EBL?:
Suspected Extended-spectrum β-Lactamases.
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S No. Antimicrobial
LS 8 LS 9 LS 10 LS 11
C T C T C T C T
1 Amikacin ≤16 >32 >32 >32 ≤16 >32 ≤16 ≤16
2 Amoxicillin/k-clavulanate ≤8/4 16-Aug 16-Aug 16-Aug ≤8/4 >16/8 >16/8 >16/8
3 Ampicillin/sulbactam 16-Aug >16/8 >16/8 >16/8 >16/8 >16/8 >16/8 >16/8
4 Ampicillin >16 >16 >16 >16 >16 >16 >16 >16
5 Aztreonam >16 >16 >16 >16 >16 >16 >16 >16
6 Cefazolin >16 >16 >16 >16 >16 >16 >16 >16
7 Cefepime >16 >16 >16 >16 >16 >16 >16 >16
8 Cefotaxime >32 >32 >32 >32 >32 >32 >32 >32
9 Cefotetan ≤16 32 ≤16 ≤16 ≤16 >32 >32 >32
10 Cefoxitin 16 >16 >16 >16 ≤8 >16 >16 >16
11 Ceftazidime >16 >16 >16 >16 >16 >16 >16 >16
12 Ceftriaxone >32 >32 >32 >32 >32 >32 >32 >32
13 Cefuroxime >16 >16 >16 >16 >16 >16 >16 >16
14 Cephalothin >16 >16 >16 >16 >16 >16 >16 >16
15 Chloramphenicol 16 ≤8 >16 >16 >16 >16 >16 >16
16 Ciprofloxacin >2 >2 >2 >2 >2 >2 >2 >2
17 ESBL-a Scrn >4 >4 >4 >4 >4 >4 >4 >4
18 ESBL-b Scrn >1 >1 >1 >1 >1 >1 >1 >1
19 Gatifloxacin >4 >4 >4 >4 4 >4 >4 >4
20 Gentamicin >8 >8 >8 >8 >8 >8 >8 >8
21 Imipenem ≤4 ≤4 ≤4 ≤4 ≤4 ≤4 ≤4 8
22 Levofloxacin >4 >4 >4 >4 >4 >4 >4 >4
23 Meropenem ≤4 8 ≤4 ≤4 ≤4 ≤4 ≤4 >8
24 Moxifloxacin >4 >4 >4 >4 >4 >4 >4 >4
25 Nitrofurantoin ≤32 >64 ≤32 ≤32 ≤32 >64 ≤32 ≤32
26 Norfloxacin >8 >8 >8 >8 >8 >8 >8 >8
27 Piperacillin/tazobactam ≤16 >64 64 ≤16 ≤16 64 >64 >64
28 Piperacillin >64 >64 >64 >64 >64 >64 >64 >64
29 Tetracycline >8 >8 >8 >8 >8 >8 >8 >8
30 Ticarcillin/k-clavulanate ≤16 >64 >64 64 ≤16 64 >64 >64
31 Tobramycin >8 >8 >8 >8 >8 >8 >8 >8
32 Trimethoprim/sulfamethoxazole >2/38 >2/38 >2/38 >2/38 ≤2/38 >2/38 >2/38 >2/38
Table 2: Minimum inhibitory concentration (MIC) of multidrug resistant lab isolates of Escherichia coli. MIC values are presented in µg/mL; C:
Control; T: Treatment; LS: Lab Isolate.
Experimental results of antimicrobial sensitivity assay showed
altered sensitivity pattern after biofield treatment in clinical isolates of
E. coli. Aztreonam, cefotaxime, ceftazidime, and ceftriaxone sensitivity
changed from EBL to R, after biofield treatment in LS 8. β-Lactamase
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production is very common mechanism of resistance in
Enterobacteriaceae family.
However, some pathogenic strains are not able to induce the
production of beta-lactamase. Continuous exposure of certain
antibiotics, results in enhanced production of AmpC beta-lactamases,
termed as induction. Amount of enzymes depends on the time and
concentration of antibiotics [24]. Biofield treatment on MDR isolates
of E. coli might alter the beta-lactamase genes, which may enhance the
production of beta-lactamase enzyme leads to resistant in case of
aztreonam, cefotaxime, ceftazidime, and ceftriaxone.
Amikacin, piperacillin/tazobactam, ticarcillin/k-clavulanate
sensitivity were altered from S to R, amoxicillin/k-clavulanate,
cefotetan, and meropenem were changed from S to I, and ampicillin/
sulbactam, cefoxitin changed from I to R, while chloramphenicol
sensitivity changed from I to S in LS 8. Sensitivity of ticarcillin/k-
clavulanate was improved i.e. from R to I, in biofield treated LS 9 as
compared to control. Piperacillin/tazobactam sensitivity altered from I
to S as compared to control in LS 9. Amikacin, amoxicillin/k-
clavulanate, cefotetan, cefoxitin, and trimethoprim/sulfamethoxazole
sensitivity changed from S to R in LS 10 after biofield treatment.
Piperacillin/tazobactam, and ticarcillin/k-clavulanate sensitivity
changed from S to I, while gatifloxacin changed from I to R in biofield
treated LS 10.
Imipenem and meropenem sensitivity changed from susceptible to
intermediate and susceptible to resistant, respectively in biofield
treated LS 11 as compared to control. Rest of antimicrobials did not
show any change in sensitivity pattern after biofield treatment.
Antimicrobial resistance can be a result of horizontal gene transfer, and
might also have unlinked point mutations of pathogenic genome [26]
biofield treatment might alter the gene transfer that could lead to alter
the sensitivity pattern of tested antimicrobials.
Estimation of minimum inhibitory concentration (MIC)
Biofield treatment on clinical isolates of MDR E. coli showed
variation in MIC values with respect to control. MIC values of control
and treated group of all the four isolates are presented in Table 2.
Biofield treatment has decreased the MIC values of some of the tested
antimicrobials such as chloramphenicol (less than 8 µg/mL) that
showed two fold decreased MIC value in LS 8, while piperacillin/
tazobactam showed four fold decreased MIC value in biofield treated
LS 9 as compared to control. Ticarcillin/k-clavulanate also showed
decreased MIC value i.e. 64 µg/mL as compared to control in LS 9.
Amikacin, amoxicillin/k-clavulanate, cefotetan, cefoxitin,
nitrofurantoin, piperacillin/tazobactam, and ticarcillin/k-clavulanate
showed increased MIC values in biofield treated LS 8 and LS 10 with
respect to control. Increase in MIC values were also reported in
ampicillin/sulbactam and meropenem in LS 8, while gatifloxacin and
trimethoprim/sulfamethoxazole in LS 10 as compared to control.
Imipenem and meropenem also showed increased MIC value as
compared to control in LS 11. An overall 40.63% antimicrobial showed
the altered MIC values out of total thirty two tested antimicrobials
among four clinical isolates.
All the four isolates had shown different variations in MIC with
respect to respective control (Figure 1). Remaining antimicrobials did
not show any change in MIC values as compared to their respective
control. Best drug prescribed by clinicians against E. coli infections.
Figure 1: Percentage change in antimicrobial sensitivity pattern,
minimum inhibitory concentrations and biochemical reactions
after biofield treatment in multi-drug resistant lab isolates of
Escherichia coli.
Growth of E. coli can be inhibited by a wide range of antimicrobial
agents. Clinicians primarily suggest a wide range of antimicrobials,
such as ciprofloxacin, levofloxacin, and trimethoprim-
sulfamethoxazole against travelers' diarrhea or associated enteric
infections [27]. Antimicrobial resistance is ever-increasing problem at
global level, but still fluoroquinolones antimicrobial are the best choice
to inhibit the growth of E. coli to treat community and hospital
acquired infections [28]. Apart from, fluoroquinolones, carbapenems
are effectively used against infections associated with extended-
spectrum-β-lactamase (ESBL) producing E. coli. Choice of treatment
depends upon the previous history like repeated UTIs, underlying
renal pathology, older males, etc. Retamar et al. studied the impact of
piperacillin/tazobactam and its MIC value in bacteremia patients, due
to ESBL producing E. coli [29]. They conclude that carbapenems are
still the best drug of choice to treat infections of ESBL producing
Enterobacteriaceae [29]. Biofield treatment on clinical MDR isolates of
E. coli had significantly reduced the MIC value of chloramphenicol
(two fold, LS 8), piperacillin/tazobactam (four fold, LS 9), and
ticarcillin/k-clavulanate (LS 9), as compared to its respective control.
Biofield treatment might act on enzymatic or genetic level which might
affect the beta-lactamases production that may lead to alter the
sensitivity pattern of tested antimicrobials.
Biochemical and biotype number study
Biochemical study was performed to test the change in biochemical
reactions among thirty three biochemicals after biofield treatment.
Results of control and treated isolates are summarized in Table 3.
Overall biochemical reactions showed 39.39% change in thirty three
biochemical reactions, as alteration in percentage value among four
isolates with respect to biochemical reactions vary with respect to its
control (Figure 1). Adonitol, citrate, esculin hydrolysis, nitrofurantoin,
inositol, malonate, tartrate, and urea showed (-) negative to (+)
positive reaction, while indole showed (+) positive to (-) negative
reaction in LS 8 as compared to control. Hydrogen sulfide showed
positive reaction and indole showed negative reaction in biofield
treated LS 9. Cetrimide and nitrofurantoin showed positive reaction
after biofield treatment in LS 10, while ornithine and raffinose showed
positive reaction in LS 11 as compared to control. Indole, nitrate,
glucose, and lactose are the positive reaction tests, while Voges-
Proskauer, and urea are the typical negative biochemical reaction test
of E. coli. Our experimental biochemical reactions in control isolates
are well supported with literature [30,31]. Rest of biochemicals did not
show any alteration in their reaction after biofield treatment.
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S No. Code Biochemical
LS 8 LS 9 LS 10 LS 11
C T C T C T C T
1 ACE Acetamide - - - - - - - -
2 ADO Adonitol - + - - - - - -
3 ARA Arabinose + + + + + + + +
4 ARG Arginine - - - - - - - -
5 CET Cetrimide - - - - - + - -
6 CF8 Cephalothin + + + + + + + +
7 CIT Citrate - + + + - - - -
8 CL4 Colistin - - - - - - - -
9 ESC Esculin hydrolysis - + - - - - - -
10 FD64 Nitrofurantoin - + - - - + - -
11 GLU Glucose + + + + + + + +
12 H2S Hydrogen sulfide - - - + - - - -
13 IND Indole + - + - + + + +
14 INO Inositol - + + + - - - -
15 K4 Kanamycin + + + + + + + +
16 LYS Lysine + + + + + + + +
17 MAL Malonate - + + + - - - -
18 MEL Melibiose + + + + + + + +
19 NIT Nitrate + + + + + + + +
20 OF/G Oxidation-Fermentation + + + + + + + +
21 ONPG Galactosidase + + + + + + + +
22 ORN Ornithine + + + + + + - +
23 OXI Oxidase - - - - - - - -
24 P4 Penicillin + + + + + + + +
25 RAF Raffinose + + - - - - - +
26 RHA Rhamnose + + + + + + + +
27 SOR Sorbitol + + + + + + + +
28 SUC Sucrose + + + + + + - -
29 TAR Tartrate - + - - - - - -
30 TDA Tryptophan deaminase - - - - - - - -
31 TO4 Tobramycin + + + + + + + +
32 URE Urea - + - - - - - -
33 VP Voges-Proskauer - - - - - - - -
Table 3: Effect of biofield treatment on multidrug resistant lab isolates of Escherichia coli to the vital processes occurring in living organisms. C:
Control; T: Treatment; LS: Lab Isolate; -: Negative; +: Positive
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Based on the altered biochemical reactions in control and treated
groups biotype numbers were observed using MicroScan Walk-Away®
using NBPC 30 panel system, which will detect the change in
biochemical reactions, and report the maximum probability of
organism on the basis of its biotype number. Out of four tested lab
isolates, three had shown change in biotype number after biofield
treatment. LS 8 showed changed in biotype number, 7774 5272 as
compared to its control, (7711 5012), while in LS 9, altered biotype
number was 7352 5072 after biofield treatment as compared to control,
7351 5072. LS 11 showed altered biotype number 5711 5012, as
compared to control biotype (5311 4012). Maximum probability of
new organism was identified as Enterobacter aerogenes in LS 8 after
biofield treatment on day 10 with respect to control organism, E. coli
(Table 4). LS 10 isolate did not show any alteration in biotype number
after treatment. Biofield treatment on pathogenic microorganisms had
been reported to alter the biochemical reactions, followed by change
biotype number and identification of new microorganism. Current
results are well corroborated with reported studies [21,22].
Isolate Group Biotype Number Organism Identification
LS 8
C 7711 5012 E. coli
T 7774 5272 Enterobacter aerogenes
LS 9
C 7351 5072 E. coli
T 7352 5072 E. coli
LS 10
C 7311 5012 E. coli
T 7311 5012 E. coli
LS 11
C 5311 4012 E. coli
T 5711 5012 E. coli
Table 4: Effect of biofield treatment on biotype number of multidrug
resistant lab isolates of Escherichia coli.
Biofield treatment is included in energy medicine under CAM with
increasing number of patients getting benefitted after this therapy
[11,32]. Mr. Trivedi’s biofield treatment in pathogenic microbes were
extensively studied and had shown a significant alteration in the
antimicrobial sensitivity pattern, biochemical reactions, and biotype
number [21,22]. Results of study conclude that, biofield treatment
might be an alternative approach to alter the antimicrobial sensitivity.
Mechanism of action through which biofield act on pathogenic
microbes, is unknown and needed to explore through in depth
research work. It can be hypothesized from the outcomes of the study
that biofield might act on receptor protein interaction of the bacterial
cell wall, which may results in altering the sensitivity of antimicrobial
after treatment [33].
Conclusion
The overall observations showed that, Mr Trivedi’s biofield
treatment on MDR isolates of E. coli induced significant alteration in
antimicrobial susceptibility pattern, MIC values, biochemical
reactions, and biotype number. A fourfold and twofold decrease in
MIC values were found in piperacillin/tazobactam, and
chloramphenicol after biofield treatment in LS 9 and LS 8 respectively.
A significant change in biochemical reactions and biotype numbers
were also observed after biofield treatment in clinical isolates of E. coli.
Based on the study outcome, Mr Trivedi’s biofield treatment could be
applied to alter the sensitivity pattern of antimicrobials, against multi-
drug resistance isolates of E. coli.
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